(Q37954675)

English

The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review

scientific article published on 27 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 August 2017

The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review (English)

1 reference

Europe PubMed Central

25 August 2017

type 2 diabetes

0 references

hospitalization

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

author name string

J H Best

1

1 reference

Europe PubMed Central

25 August 2017

K Lavillotti

2

1 reference

Europe PubMed Central

25 August 2017

M B DeYoung

3

1 reference

Europe PubMed Central

25 August 2017

L P Garrison

4

1 reference

Europe PubMed Central

25 August 2017

publication date

27 December 2011

1 reference

Europe PubMed Central

25 August 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

25 August 2017

14

1 reference

Europe PubMed Central

25 August 2017

5

1 reference

Europe PubMed Central

25 August 2017

387-398

1 reference

Europe PubMed Central

25 August 2017

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide therapy in insulin-treated type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Standards of medical care in diabetes--2011.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01533.X

1 reference

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37954675&oldid=2122494786"